News Release

International Trademark fully registered for NAVCO BIOACTIVE® Vancouver, British Columbia - (September 17, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”), reports that it has received full international registration and certification in respect of the trademark of NAVCO BIOACTIVE® through the U.S. Patent and Trademark Office and the World Intellectual Property Organization. The jurisdictions covered include the European Union, United Kingdom, USA and international. The classification of goods and or services for which this trademark applies includes hand-sanitizing preparations, antibacterial and anti-viral topical applications for providing longer-lasting skin protection against bacterial and viral infections.

The Company plans to use this Navco Bioactive® trademark in the branding and marketing of its line of novel silver nanoparticle based antimicrobial skin shield and wound-healing skin care products. Navco’s antimicrobial skin sprays are formulated with natural and known compounds, are alcohol free, and are designed to minimize skin irritation and toxicity and to maximize healthy skin function.

About the Company

Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, fungi, viruses, and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methodsof-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health.

For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Silver Nanoparticle Skin Shield Spray Receives Health Canada Natural Product License

Vancouver, British Columbia-(September 3, 2024) Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”), has received a Health Canada Natural Health Product licence (“NPN”) for its antibacterial - antimicrobial skin shield and wound spray. This is Navco’s first Health Canada product approval for a topical spray designed to help protect and cleanse against germs and to treat minor skin wounds and infections utilizing proprietary silver nanoparticle technology as its method of action.

Navco’s NPN-licensed topical spray cleanses and protects the skin against bacteria, microbes, viruses, fungi, and other pathogens. Navco’s silver nanoparticles destroy bacteria-microbes on contact and provide a longer-term barrier and protective coating to the skin. They are also effective with minor wounds, burns, and moisturizing and rejuvenating to the skin. The proprietary development of these silver nanoparticles results in significantly increased bioavailability and builds upon the wealth of knowledge associated with the benefits of novel methods of action using silver treatment. Navco’s antimicrobial spray is formulated with natural and known compounds, is alcohol free, is designed to minimize skin irritation and toxicity and to maximize healthy skin function.

“We are excited about bringing Navco’s innovative, proprietary, silver nanoparticle based alcohol-free skin care solutions to consumers. With an increasing awareness and concern over the impact that existing products can have on human skin, such as the significant rise in skin conditions like eczema, Navco’s antimicrobial skin shield product can offer a more effective and dermatologically friendly alternative”, said Marek Jasinski, COO of Navco Pharma. “We aim to meet the growing consumer demand for novel, enhanced, sustainable skincare and germ prevention solutions.”

About the Company

Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, fungi, viruses, and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861- 8980.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize.

Vancouver, British Columbia--(July 8, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”) announces the results of its Annual General Meeting (“AGM”) held on June 4, 2024, in Vancouver, B.C. All resolutions presented to the shareholders as set out in the Company’s Notice of Meeting and Information Circular, both dated May 2, 2024, were approved. The number of Directors was fixed at four with the following nominees elected as Directors: Marek Jasinski, Thomas Jusdanis, Jatinder Dhaliwal and Judy Su. K.R. Margetson, Chartered Professional Accountants, was appointed as the auditor of the Company for the ensuing year, at a remuneration to be fixed by the directors. The Company also announces that a new form 10% “rolling” share option plan dated for reference April 22, 2024 (the “New Option Plan”), a complete copy of which was attached as Schedule “B” to the Company’s Information Circular for the AGM, was approved by the shareholders of the Company at the AGM and by the TSX Venture Exchange, which is available for viewing under the Company’s SEDAR+ corporate profile at www.sedarplus.ca. The New Option Plan was created to comply with the requirements of the new TSX Venture Exchange policy governing security-based compensation which became effective November 24, 2021. One of the provisions to the Company’s New Option Plan is allowing option holders to exercise options on a "Cashless Exercise" or "Net Exercise" basis.

About the Company

Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods- of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health.

For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Forward-Looking Statements

This news release contains certain forward-looking statements, including, but not limited to, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. The Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Next Generation Antimicrobial Line Readies for Commercial Launch

Vancouver, British Columbia--(June 4, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”), is now positioning itself to launch and commercialize its line of antimicrobial topical consumer products that provide active protection against microorganisms to help reduce the spread of bacteria, fungi, and infectious diseases. The line includes topical applications (spray and cream) for hand and skin cleansing, therapeutic treatment and for physical surfaces that does not allow the development of bacterial resistance. The lines’ innovative nanoparticle derived products combine natural and known compounds, including silver.

Antimicrobial Resistance (“AMR”) occurs when bacteria, fungi, viruses and parasites no longer respond to antimicrobial medicines. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become difficult or impossible to treat, increasing the risk of disease spread, severe illness, disability and death. Navco’s line of antimicrobial products can help reduce the spread of these microbes in various consumer and medical settings.

According to Precedence Research, the Global Antibacterial Products market (e.g.: body moisturizer, hand cream & lotion, facial cleanser, hand soaps & sanitizers, body wash etc.) was valued at USD $32.4 billion in 2023 and is anticipated to grow at a CAGR of 5.75% from 2024 to 2033. Increased awareness of the value of upholding cleanliness and hygiene to stop the transmission of illnesses and germs is propelling this global market.

“We are pleased to be moving towards the production and launch phase of our line of antimicrobial nano-products as they have been years in development and verification and can be a real game changer when it comes to reducing infections and protecting good health”, said Geoff Lee, CEO of Navco Pharma.

About the Company

Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, fungi, viruses, and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health.

For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize.

Vancouver, British Columbia--(April 12, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”), announces that it has entered a contract with SOF Marketing for $300,000 CAD to broaden the company's reach within the investment community, to increase investor awareness of the company, and to attract potential new investors through various on-line platforms and methods of engagement. The marketing services include project management, rebranding, social media marketing, consulting for an on-line marketing campaign, co-ordinating marketing actions, maintaining and optimizing AdWords campaigns, adapting AdWords bidding strategies, optimizing AdWords ads, and creating and optimizing landing pages. The promotional activity will include e-mail, Facebook and Google and will last till October 12, 2024.

About the Company

Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skincare, household & institutional products and veterinary health.

For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Neither the TSX Venture Exchange nor its Regulation Services

Provider (as that term is defined in policies of the TSX Venture

Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize.

Vancouver, British Columbia--(March 14, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”, formerly, BMGB Capital Corp.) announces that it has granted an aggregate of 3,900,000 stock options (the “Options”) to certain officers, directors and consultants of the Company to purchase 3,900,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s stock option plan. The Options are exercisable at a price of $0.05 per Share for a period of 10 years from the date of grant. The Options shall vest immediately in accordance with the Company’s stock option plan dated for reference June 15, 2018. About the Company Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methodsof-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forwardlooking information to vary from those described herein should one or more of these risks or uncertainties materialize.

Vancouver, British Columbia--(January 30, 2024) - Navco Pharmaceuticals

Inc. (TSXV: NAV) (“Navco” or the “Company”, formerly, BMGB Capital

Corp.) announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on April. 13, 2023.

An aggregate of 14,070,441 Warrants were initially issued with an exercise

price of $0.25 per common share of the Company (a “Common Share”) in connection with a public offering of 14,070,441 units at a price of $0.15 per Unit (the “Units”). The Company intends to amend the exercise price of the unexercised Warrants to $0.10 per Common Share.

The Warrants, as amended, will be subject to an accelerated expiry provision

such that if for any ten consecutive trading days (the “Premium Trading

Days”) during the unexpired term of the Warrants, the closing price of the Company’s common shares on the TSX Venture Exchange (the “TSXV”) exceeds $0.125 (representing the amended Warrant exercise price of $0.10 plus 25%), the exercise period of the Warrants will be reduced to 30 days,

starting seven days after the last Premium Trading Day. The Company will announce any such accelerated expiry date by press release. All other terms of the Warrants remain unchanged.

Amendment of the Warrants is subject to the approval of the TSXV. It is also a pre-condition that the Company obtain the written consent of all Warrant-

holders to the amendments described above. Accordingly, the Company will obtain the consent of all Warrant-holders prior to applying to the TSXV for approval of the amendments mentioned in this news release. The Company has also confirmed that no Warrants have been exercised and no Warrants are held by insiders of the Company.

About the Company

Navco is a Burlington, Ontario – based company that is building a leading

market position in the use of nanotechnology to develop and commercialize

novel products against bacteria, viruses, fungi and infectious diseases. Navco

has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Neither the TSX Venture Exchange nor its Regulation Services

Provider (as that term is defined in policies of the TSX Venture

Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute “forward-looking

information” as such term is defined in applicable Canadian securities

legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”,

“seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and

similar expressions as they relate to the Company are intended to identify

forward-looking information. All statements other than statements of

historical fact may be forward-looking information. Such statements reflect

the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks,

uncertainties and assumptions. Many factors could cause the actual results,

performance or achievements that may be expressed or implied by such

forward-looking information to vary from those described herein should one

or more of these risks or uncertainties materialize.

Vancouver, British Columbia--(January 18, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”, formerly, BMGB Capital Corp.) is pleased to announce that, further to its news release dated December 11, 2023, it has completed the acquisition (the “Acquisition”) of all the issued and outstanding shares of SL Immuno Pharma Corp. (“SL Immuno”) pursuant to the terms of a share exchange agreement dated December 11, 2023 (the “Share Exchange Agreement”) between the Company, Navco and the shareholders of SL Immuno (the “SL Immuno Shareholders”). SL Immuno is a pharmaceutical company that is looking to improve drug delivery and natural clean lifestyle options for everyday people. SL Immuno has formulated sublingual strips (the “MunoStrips”) infused with some of the most powerful immune-boosting compounds known to science to help maintain immune function and help support the body’s metabolism. MunoStrips offer a precise, rapid, discreet, and healthier option to help support immune function. The MunoStrips product line has been scientifically developed to integrate easily into everyday life and most daily activities. Navco will look to get this acquisition, along with its line of Health Canada registered NAVCO BioActive™ topical antibacterial skin cleanser and treatment products and NAVCO BioGuard™ antiviral oral products, onto pharmaceutical shelves across the country. BioActive™ and BioGuard™ are revolutionary non-toxic, alcohol and chemical-free and non-flammable nanoproducts that protect against germs and microorganisms. In connection with the Acquisition, the Company issued an aggregate of 16,719,100 common shares in the capital of the Company (the “Payment Shares”) pro rata to the SL Immuno Shareholders at a deemed price of $0.05 per Payment Share. For additional details regarding the Acquisition and SL Immuno’s business and operations, please refer to the Company’s news release dated December 11, 2023,available under the Company’s SEDAR+ profile at www.sedarplus.ca. In conjunction with and upon closing of the Acquisition, two members of the Company’s Board of Directors, Dr. Akbar Khan and Mr. Peter Espig resigned from the Board of Directors, and SL Immuno nominees, Mr. Jatinder “Jay” Dhaliwal and Ms. Judy Su, were appointed as directors of the Company to fill the vacancies created by those resignations. The Company would also like to take this opportunity to thank Dr. Khan and Mr. Espig for all of their contributions as directors of the Company, and to welcome Mr. Dhaliwal and Ms. Su to its Board. About the Company Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; commercialization of the Company’s product line; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company assumes no responsibility for the accuracy or completeness of such forwardlooking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Vancouver, British Columbia, December 11, 2023 - Navco Pharmaceuticals Inc. (TSXV: NAV) (“Navco” or the “Company”, formerly, BMGB Capital Corp.) is pleased to announce that it has entered into a share exchange agreement dated December 11, 2023 with SL Immuno Pharma Corp. (“SL Immuno”) and its shareholders (the “SL Immuno Shareholders”) pursuant to which the Company will acquire all of the issued and outstanding common shares of SL Immuno (the “SL Immuno Shares”) in exchange for common shares of NAVCO (the “NAVCO Shares”) on a 1:1 exchange ratio (the “Acquisition”). The Acquisition is an arm’s length transaction and no finder’s fees are paid in connection with the Acquisition. About SL Immuno Pharma Corp. SL Immuno is a pharmaceutical company that is looking to improve drug delivery and natural clean lifestyle options for everyday people. SL Immuno has formulated sublingual strips infused with some of the most powerful immune-boosting compounds known to science to help maintain immune function and help support the bodies metabolism (the “MunoStrips”). MunoStrips offer a precise, rapid, discreet, and healthier option to help support immune function. The MunoStrips product line has been scientifically developed to integrate easily into everyday life and most daily activities. The Acquisition Pursuant to the Acquisition, NAVCO will acquire all the shares of SL Immuno for an aggregate purchase price of $835,855 (the “Purchase Price”) which will be satisfied by NAVCO issuing pro rata to the SL Immuno Shareholders 16,719,100 NAVCO Shares (the “NAVCO Payment Shares”) at a deemed price of $0.05 per NAVCO Payment Share. The NAVCO Payment Shares will be the sole consideration received by the SL Immuno Shareholders in exchange for the SL Immuno Shares. The Share Exchange Agreement includes customary conditions precedent to the closing of the Acquisition, including receipt of all necessary regulatory, corporate approvals, compliance with all applicable regulatory requirements, and all requisite board approvals being obtained. Certain of the NAVCO Payment Shares issuable pursuant to the Acquisition may be subject to escrow requirements pursuant to TSX-V policy and hold periods as required by applicable securities laws. Board of Directors Changes In conjunction with and upon closing of the Acquisition, Mr. Jatinder (Jay) Dhaliwal and Ms. Judy Su will be joining the board of directors of the Company. Mr. Peter Espig and Dr. Akbar Khan will be resigning from the board. The Company would like to thank Mr. Espig and Dr. Khan for they’re contributions to the growth of Navco. Mr. Dhaliwal is a registered pharmacist, CEO and director of multiple publicly traded companies listed in Canadian (CSE, TSX) and American (Nasdaq) exchanges. Mr. Dhaliwal is currently a director of a leading seed to patient cannabis producer based out of Europe and currently listed on the Nasdaq. In addition, he is an independent director of a Nasdaq listed premier marketing agency specialized in the liquor industry. He has been and currently acts as CEO of a large retail cannabis operation, giving him an in depth knowledge at dealing with government agencies associated with liquor and cannabis boards. He has worked in an upper management role in a large national banner pharmacy utilizing his skills to drive growth at the consumer level and savings through supply chain negotiations. He has extensive knowledge in agricultural, medical, and pharmaceutical operations. Mr. Dhaliwal holds a Bachelor of Pharmacy from the University of British Columbia and a Bachelor of Science in biology from the University of Victoria. Mr. Dhaliwal has overseen the acquisition and development of numerous projects, technology platforms and applications. He has overseen operations of numerous retail and commercial operations and implemented various health protocols and technology advances into health and wellness chains. Ms. Su graduated in 2012 at the University of British Columbia with bachelor's degree in pharmacy. She was lead pharmacist at a national drug store for four years and has a vast understanding of large-scale retail distribution of scheduled drugs and medications. Currently, she works as a pharmacist in the public sector, where she is instrumental in pharmaceutical practices of the province. About the Company Navco is a Burlington, Ontario – based company that is building a leading market position in the use of nanotechnology and artificial intelligence to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved science that supports its particle science. The Company’s pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health product needs using nanoparticles from natural & known compounds with an optimized and high degree of efficacy; and are non-toxic and alcohol free. Target markets include human health & wellness, personal skin care, household & institutional products, and veterinary health. For additional information, please refer to the Company’s disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the closing of the Acquisition as contemplated or at all, obtaining the TSX-V’s approval of the Acquisition, and the appointment of SL Immuno’s nominees to the Company’s board of directors. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company assumes no responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - Navco Pharmaceuticals Inc. (TSXV: NAV) ("Navco" or the "Company", formerly known as BMGB Capital Corp.) is pleased to announce that it has successfully completed its previously announced "Qualifying Transaction", as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Navco Pharmaceuticals Limited ("NPL") and as described in the Company's Exchange Filing Statement dated November 28, 2022 and available on SEDAR at www.sedar.com.

The Qualifying Transaction

Pursuant to a share exchange agreement (the "Share Exchange Agreement") dated as of January 18, 2021, as amended between the Company, NPL, and the NPL shareholders, the Company has acquired all of the issued and outstanding common shares of NPL by issuing an aggregate of 21,340,000 Company common shares pro rata to the NPL shareholders at deemed price of $0.15 per share, representing an aggregate purchase price of $3,201,000. In connection with the Qualifying Transaction, the Company also closed a private placement financing for gross proceeds of $2,110,566 (further described below) and issued 340,000 finder's shares to an arm's length third party.

On closing of the Qualifying Transaction (including the private placement described below), there are 40,350,441 Company common shares issued and outstanding. The shareholders of the Company who held shares prior to closing now hold approximately 11.40% of the shares, participants in the private placement hold approximately 34.87% of the shares, the former NAV shareholders hold approximately 52.89% of the shares, and the arm's length finder holds approximately 0.84% of the shares.

Final acceptance of the Qualifying Transaction will occur upon the issuance of the Final Exchange Bulletin (the "Exchange Bulletin") by the Exchange. Subject to final acceptance by the Exchange, the Company will be classified as a 'Life Sciences' issuer pursuant to Exchange policies and its common shares are expected to commence trading on the Exchange on or about April 18, 2023.

The Private Placement

Concurrent to completion of the Qualifying Transaction, the Company closed a private placement financing for gross proceeds of $2,1110,566 through the issuance of an aggregate of 14,070,441 units (each a "Unit") at a price of $0.15 per Unit. Each Unit is comprised of one common share of the Company and one common share purchase warrant exercisable for an additional share for two years at an exercise price of $0.25. The shares and warrants issued under the financing are subject to a four month hold period which expires August 14, 2023. The Company did not pay any finder's fees or issue any finder's securities in connection with the financing.

Escrowed Securities

Pursuant to the terms of an Exchange Tier 2 Value Security Escrow Agreement among the Company, Computershare Investor Services Inc. (as escrow agent) and certain Company shareholders, an aggregate of 9,605,943 shares have been placed in escrow. In addition, an aggregate of 2,000,000 shares are subject to an Exchange CPC Escrow Agreement.

Directors and Officers

Following closing of the Qualifying Transaction, the directors and officers of Navco are:

Geoffrey Lee, CEO
Marek Jasinski, Director and Chief Operating Officer